missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD71 Mouse Anti-Rat, Brilliant Violet 650, Clone: OX-26, BD Optibuild™
Mouse Monoclonal Antibody
Brand: BD Biosciences 744416
This item is not returnable.
View return policy
Description
The OX-26 monoclonal antibody specifically recognizes the transferrin receptor which is also known as CD71. CD71 is expressed on proliferating cells and brain endothelium. The OX-26 antibody does not block transferrin binding to its receptor.
The antibody was conjugated to BD Horizon™ BV650 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405nm and an acceptor dye with an Em Max at 650nm. BD Horizon BV650 can be excited by the violet laser and detected in a filter used to detect APC-like dyes (eg, 660/20nm filter). Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor™ 700 detectors. However, the spillover can be corrected through compensation as with any other dye combination. BV650 is a tandem fluorochrome of BD Horizon BV421 and an acceptor dye with an emission maximum at 650 nm. Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor™ 700 detectors. BV650 will have moderate spillover into the BD Horizon™ BV711 detector.
Specifications
| CD71 | |
| OX-26 | |
| Brilliant Violet 650 | |
| CD71, Transferrin Receptor, TfR, TfR1, Tfrc, Trfr, TR | |
| PHA-activated PVG rat lymph node cells | |
| 50 μg | |
| Primary | |
| Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. |
| Monoclonal | |
| 0.2mg/mL | |
| Aqueous buffered solution containing ≤0.09% sodium azide. | |
| Mouse | |
| Affinity Purified | |
| RUO | |
| Mouse | |
| IgG2a κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction